Delving into the Latest Updates on Wanbangde Pharmaceutical Holding Group Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	4
Endocrinology and Metabolic Disease	4
Immune System Diseases	3
Neoplasms	2
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2
Synthetic peptide	2
Chemical drugs	1

Top 5 Target	Count

DNMT1(DNA (cytosine-5)-methyltransferase 1)	1
SCNA(Sodium voltage-gated channel alpha subunits)	1
MC4R(Melanocortin receptor 4)	1
ACHE x NMDA receptor	1
MC1R(Melanocortin receptor 1)	1

In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID). Ten healthy study participants will be enrolled in each dose group, and randomized to the investigational drug group or the placebo group in a 4:1 ratio (i.e., 8 study participants in the investigational drug group and 2 study participants in the placebo group). An appropriate gender ratio will be ensured within each dose group.

Start Date25 Aug 2026

Sponsor / Collaborator

Wepon Pharmaceuticals Group Co. Ltd.

CTR20255231

/ CompletedPhase 1

石杉碱甲口服溶液与石杉碱甲注射液在中国健康受试者中的单中心、随机、开放、单次给药、两周期、两序列、交叉设计的药代动力学比较研究

[Translation] A single-center, randomized, open-label, single-dose, two-period, two-sequence, crossover pharmacokinetic comparison study of huperzine A oral solution and huperzine A injection in healthy Chinese subjects.

主要试验目的：比较石杉碱甲口服溶液和石杉碱甲注射液在中国健康受试者空腹状态下单次给药的药代动力学特征。次要试验目的：1）评估石杉碱甲口服溶液的相对生物利用度 2) 评估空腹状态下两种制剂的安全性。

[Translation]

Primary objective: To compare the pharmacokinetic characteristics of huperzine A oral solution and huperzine A injection in healthy Chinese subjects after a single fasting dose. Secondary objectives: 1) To assess the relative bioavailability of huperzine A oral solution; 2) To assess the safety of the two formulations in a fasting state.

Start Date12 Jan 2026

Sponsor / Collaborator

Wepon Pharmaceuticals Group Co. Ltd.

100 Clinical Results associated with Wanbangde Pharmaceutical Holding Group Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Wanbangde Pharmaceutical Holding Group Co., Ltd.

Login to view more data

100 Deals associated with Wanbangde Pharmaceutical Holding Group Co., Ltd.

Login to view more data

100 Translational Medicine associated with Wanbangde Pharmaceutical Holding Group Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Oct 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 1

Phase 3

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ambroxol Hydrochloride ( SCNA )	Chronic lung disease More	Phase 3
Novel MCR cyclic peptide (Wepon Pharmaceuticals) ( MC4R )	Diabetic Nephropathies More	Preclinical
Mecobalamin ( DNMT1 )	Amyotrophic Lateral Sclerosis More	Preclinical
Afamelanotide Acetate ( MC1R )	Pemphigus More	Preclinical
Huperzine A ( ACHE x NMDA receptor )	Memory Disorders More	Pending